Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEO-VC: Neoadjuvant Triple Therapy in Melanoma
NCT02303951Phase 2Terminated
- Sponsor
- University Hospital Tübingen
- Start
- Jan 2015
- Primary completion
- May 2020
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of atezolizumab in Malignant Melanoma (MM), sponsored by University Hospital Tübingen. Started Jan 2015; status: terminated.
02
Drugs
atezolizumab
03
Conditions
Malignant Melanoma (MM)
Beyond the preview
Go deeper on NCT02303951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02303951.